Effect of Macrolide Antibiotics on Airway Inflammation in People With Chronic Obstructive Pulmonary Disease (COPD)

• Status: Completed
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Chronic obstructive pulmonary disease (COPD) is a chronic lung disease. Azithromycin, an antibiotic, may be beneficial at reducing the symptoms and severity of the disease. This study will analyze previously collected study data to evaluate the anti-inflammatory properties of azithromycin and determine how azithromycin affects the frequency and severity of COPD exacerbations.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Alabama at Birmingham
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Azithromycin

Criteria

Inclusion Criteria:

• Participating in the COPD Network Macrolide study

• Clinical diagnosis of at least moderate COPD

• Cigarette consumption of 10 pack years or more

Exclusion Criteria:

• Diagnosis of asthma

• Predicted life expectancy of less than 3 years

• History of hypersensitivity to macrolide antibiotics

• Long-term kidney insufficiency

• Long-term liver insufficiency

• Prolonged QT interval

• Use of medications that may prolong the QT interval